Cara Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.74
Dividend & YieldN/A$ (N/A)
Beta 0.92
Market capitalization 592.14M
Operating cash flow -56.47M
ESG Scores unknown

Company description

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 5.12M 6.04M -2.78M -1.02M
Total Cashflows From Investing Activities -82.82M -30.52M -20.27M -4.75M
Net Borrowings
Total Cash From Financing Activities 110.81M 142.6M 39.14M 46.61M
Change To Operating Activities -3.17M -4.94M -4.31M 7.96M
Issuance Of Stock 110.81M 142.6M 39.14M 46.61M
Net Income -74.01M -106.37M 8.41M -88.44M
Change In Cash 5.69M 2.86M 13.38M -18.23M
Effect Of Exchange Rate
Total Cash From Operating Activities -22.3M -109.22M -5.49M -60.09M
Depreciation 370k 799k 1.01M 1.55M
Change To Account Receivables -803k -45k 414k 102k
Other Cashflows From Financing Activities
Change To Netincome 50.13M -4.56M -7.54M 21.54M
Capital Expenditures -73k -18k -349k -39k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 113.82M 113.82M
Income Before Tax -74.4M -107.19M 7.72M -88.44M
Net Income -74.01M -106.37M 8.41M -88.44M
Selling General Administrative 15.32M 17.75M 21.85M 29.41M
Gross Profit -62.06M -93.93M 27.23M -59.67M
Ebit -77.38M -111.68M 5.38M -89.08M
Operating Income -77.38M -111.68M 5.38M -89.08M
Interest Expense
Income Tax Expense -389k -816k -691k
Total Revenue 13.47M 19.89M 135.08M 23.03M
Cost Of Revenue 75.53M 113.82M 107.85M 82.7M
Total Other Income ExpenseNet 2.98M 4.49M 2.33M 642k
Net Income From Continuing Ops -74.01M -106.37M 8.41M -88.44M
Net Income Applicable To Common Shares -74.01M -106.37M 8.41M -88.44M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 57.19M 46.25M 22.16M 19.53M
Total Stockholder Equity 133.63M 186.71M 249M 227.52M
Other Current Liabilities 26.82M 22.26M
Total Assets 190.82M 232.96M 271.16M 247.06M
Common Stock 39k 47k 50k 53k
Other Current Assets 361k
Retained Earnings -294.35M -400.73M -392.32M -480.76M
Treasury Stock -114k 170k 73k -358k
Cash 15.08M 18.3M 31.68M 13.45M
Total Current Liabilities 40.45M 42.89M 18.48M 17.62M
Other Stockholder Equity -114k 170k 73k -358k
Property, Plant, and Equipment 880k 3.74M 5.12M 3.6M
Total Current Assets 168.14M 165.66M 195.06M 173.29M
Net Tangible Assets 133.63M 186.71M 249M 227.52M
Net Receivables 1.59M 1.79M 2.06M 1.15M
Accounts Payable 4.37M 9.1M 4.89M 5.62M


Insider Transactions

Here are the insider transactions of stock shares related to Cara Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
POSNER CHRISTOPHERSale at price 11.13 per share.D2022-11-16Chief Executive Officer14.47k
VOGELBAUM MARTIN ASale at price 10.28 per share.D2022-09-14Director10.8k
BAINS HARRISON M JRSale at price 9.05 per share.D2022-07-15Director7.2k
IVES JEFFREY LSale at price 9.05 per share.D2022-07-15Director3.6k
MAKARA RICHARDStock Award(Grant) at price 0.00 per share.D2022-06-15Officer7.5k
BAINS HARRISON M JRStock Award(Grant) at price 0.00 per share.D2022-06-02Director11.88k
VOGELBAUM MARTIN AStock Award(Grant) at price 0.00 per share.D2022-06-02Director35.63k
IVES JEFFREY LStock Award(Grant) at price 0.00 per share.D2022-06-02Director11.88k
SHIFF SUSANStock Award(Grant) at price 0.00 per share.D2022-06-02Director11.88k
POSNER CHRISTOPHERSale at price 12.67 per share.D2022-04-04Chief Executive Officer2.01k
MENZAGHI FREDERIQUESale at price 11.91 per share.D2022-04-01Officer1.78k
TERRILLION SCOTT MSale at price 11.91 per share.D2022-04-01General Counsel1.64k
GONCALVES JOANASale at price 11.91 per share.D2022-04-01Officer1.64k
TERRILLION SCOTT MSale at price 11.38 per share.D2022-03-03General Counsel1.79k
REILLY THOMAS CHARLESSale at price 11.38 per share.D2022-03-03Chief Financial Officer2.04k
TERRILLION SCOTT MStock Award(Grant) at price 0.00 per share.D2022-02-28General Counsel25.33k
REILLY THOMAS CHARLESStock Award(Grant) at price 0.00 - 10.29 per share.D2022-02-28Chief Financial Officer25.33k
MENZAGHI FREDERIQUEStock Award(Grant) at price 0.00 per share.D2022-02-25Officer20k
MENZAGHI FREDERIQUESale at price 10.29 per share.D2022-02-25Officer2.11k
TERRILLION SCOTT MSale at price 10.29 per share.D2022-02-25General Counsel1.97k
POSNER CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2022-02-25Chief Executive Officer39k
GONCALVES JOANAStock Award(Grant) at price 0.00 per share.D2022-02-25Officer20k
GONCALVES JOANASale at price 10.29 per share.D2022-02-25Officer1.97k
MENZAGHI FREDERIQUEStock Award(Grant) at price 0.00 per share.D2021-12-17Officer12.61k
TERRILLION SCOTT MStock Award(Grant) at price 0.00 per share.D2021-12-17General Counsel11.49k
GONCALVES JOANAStock Award(Grant) at price 0.00 per share.D2021-12-17Officer12.61k
REILLY THOMAS CHARLESStock Award(Grant) at price 0.00 per share.D2021-12-17Chief Financial Officer11.17k
IVES JEFFREY LSale at price 16.04 per share.D2021-11-12Director8.18k
GONCALVES JOANASale at price 17.15 per share.D2021-11-01Officer1k
POSNER CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2021-10-29Director147.94k
GONCALVES JOANASale at price 15.00 per share.D2021-10-27Officer1k
CHALMERS DEREK TSale at price 15.47 per share.D2021-09-07Chief Executive Officer20k
CHALMERS DEREK TSale at price 14.20 per share.D2021-08-30Chief Executive Officer8.44k
MENZAGHI FREDERIQUESale at price 14.20 per share.D2021-08-30Officer3.85k
TERRILLION SCOTT MSale at price 14.20 per share.D2021-08-30General Counsel1.76k
GONCALVES JOANASale at price 14.20 per share.D2021-08-30Officer2.11k
REILLY THOMAS CHARLESSale at price 14.20 per share.D2021-08-30Chief Financial Officer1.98k
CHALMERS DEREK TStock Award(Grant) at price 0.00 per share.D2021-08-24Chief Executive Officer17.33k
MENZAGHI FREDERIQUEStock Award(Grant) at price 0.00 per share.D2021-08-24Officer9.6k
TERRILLION SCOTT MStock Award(Grant) at price 0.00 per share.D2021-08-24General Counsel5.33k
GONCALVES JOANAStock Award(Grant) at price 0.00 per share.D2021-08-24Officer6.4k
REILLY THOMAS CHARLESStock Award(Grant) at price 0.00 per share.D2021-08-24Chief Financial Officer5.33k
VOGELBAUM MARTIN ASale at price 13.05 per share.D2021-06-07Director8.64k
IVES JEFFREY LSale at price 13.05 per share.D2021-06-07Director2.52k
POSNER CHRISTOPHERSale at price 13.04 per share.D2021-06-07Director2.3k
BAINS HARRISON M JRStock Award(Grant) at price 0.00 per share.D2021-06-03Director7.2k
VOGELBAUM MARTIN AStock Award(Grant) at price 0.00 per share.D2021-06-03Director14.4k
IVES JEFFREY LStock Award(Grant) at price 0.00 per share.D2021-06-03Director7.2k
POSNER CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2021-06-03Director7.2k
SHIFF SUSANStock Award(Grant) at price 0.00 per share.D2021-06-03Director7.2k
GONCALVES JOANASale at price 27.63 per share.D2021-04-21Officer3k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cara Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cara Therapeutics Inc

Here is the result of two systematic investment strategies applied to Cara Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cara Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cara Therapeutics Inc:

Cara Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -2.94% on the backtest period.

Performance at glance

Performance

-2.94 %

Latent gain

-52.0 $

Invested capital

1769.44 $

Annualized return

-0.72 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cara Therapeutics Inc

This is the result of two momentum investment strategies applied to Cara Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cara Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Cara Therapeutics Inc:

Cara Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 15.36% of return on Cara Therapeutics Inc. That represents 812.27$ of latent gain with 5288.22$ of employed capital.
  • The second momentum investment strategy would give 16.31% of return on Cara Therapeutics Inc. That represents 411.49$ of latent gain with 2522.47$ of employed capital.
Performance at glance (1Q Momentum)

Performance

15.36 %

Latent gain

812.27 $

Invested capital

5288.22 $

Annualized return

3.51 %
Performance at glance (2Q Momentum)

Performance

16.31 %

Latent gain

411.49 $

Invested capital

2522.47 $

Annualized return

4.51 %

Momentum equity curve on Cara Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Cara Therapeutics Inc:

Cara Therapeutics Inc momentum equity

Note: the dividends potentially given by Cara Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cara Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cara Therapeutics Inc since the beginning:

Cara Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cara Therapeutics Inc

Buy the dip entry openings on Cara Therapeutics Inc

Cara Therapeutics Inc

The performance achieved by the robo-advisor on Cara Therapeutics Inc is 7.37%. That represents 36.83$ of latent gain with 499.88$ of employed capital. The following chart shows Cara Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cara Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

7.37 %

Latent gain

36.83 $

Invested capital

499.88 $

Annualized return

3.51 %

Equity curve of the strategy applied to Cara Therapeutics Inc

The following chart shows the result of the investment strategy applied to Cara Therapeutics Inc:

Cara Therapeutics Inc

Note: the dividends potentially given by Cara Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cara Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cara Therapeutics Inc:

Cara Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cara Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Cara Therapeutics Inc.

Equity curve comparison on Cara Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cara Therapeutics Inc investment strategy comparison

Employed capital comparison on Cara Therapeutics Inc

Cara Therapeutics Inc investment comparison

Performance comparison on Cara Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -2.94% -52.0$ 1769.44$ -0.72%
Momentum 1 quarter 15.36% 812.27$ 5288.22$ 3.98%
Momentum 2 quarters 16.31% 411.49$ 2522.47$ 4.51%
Non-directional 7.37% 36.83$ 499.88$ 3.51%
Annualized return comparison

Automatic investment

-0.72 %

Momentum 1Q

4.51 %

Momentum 2Q

4.51 %

Non-directional

3.51 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cara Therapeutics Inc:

Note: The algorithm computes the probability of correlation between Cara Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cara Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Cara Therapeutics Inc
Country United States
City Stamford
Address 4 Stamford Plaza
Phone 203 406 3700
Website www.caratherapeutics.com
FullTime employees 84
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker CARA
Market www.nasdaq.com

Cara Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown